CUSIP 98937L105 · who reports it, how much, and how much it matters to them
26 of the 720 hedge fund managers we track reported shares of Zenas BioPharma, Inc. (Nasdaq: ZBIO) on Form 13F for 30 June 2026. Between them they reported USD 267m. The largest position belongs to Polar Capital LLP, at USD 61m. The manager with the most riding on it is Fairmount Funds Management, where it is 4.0% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Polar Capital LLP26 funds on PPLI.com | USD 61m | 0.1% |
| 2 | Fairmount Funds Management2 funds on PPLI.com | USD 60m | 4.0% |
| 3 | Two Sigma Investments35 funds on PPLI.com | USD 21m | 0.0% |
| 4 | ECOR1 Capital3 funds on PPLI.com | USD 20m | 1.0% |
| 5 | Millennium Management6 funds on PPLI.com | USD 17m | 0.0% |
| 6 | Balyasny Asset Management25 funds on PPLI.com | USD 15m | 0.0% |
| 7 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 15m | 0.6% |
| 8 | Rock Springs Capital Management2 funds on PPLI.com | USD 13m | 0.6% |
| 9 | Marshall Wace LLP84 funds on PPLI.com | USD 8.2m | 0.0% |
| 10 | Sphera Funds Management1 fund on PPLI.com | USD 5.9m | 0.8% |
| 11 | Walleye Capital8 funds on PPLI.com | USD 5.3m | 0.0% |
| 12 | Sio Capital Management4 funds on PPLI.com | USD 5.3m | 0.9% |
| 13 | Citadel Advisors32 funds on PPLI.com | USD 5m | 0.0% |
| 14 | Voleon Capital Management13 funds on PPLI.com | USD 4.2m | 0.1% |
| 15 | Squarepoint Ops7 funds on PPLI.com | USD 3.2m | 0.0% |
| 16 | Verition Fund Management3 funds on PPLI.com | USD 1.9m | 0.0% |
| 17 | J. Goldman & Co.1 fund on PPLI.com | USD 1.7m | 0.0% |
| 18 | Exome Asset Management2 funds on PPLI.com | USD 1.3m | 0.8% |
| 19 | Burkehill Global Management5 funds on PPLI.com | USD 1m | 0.0% |
| 20 | Atom Investors1 fund on PPLI.com | USD 943,000 | 0.1% |
| 21 | Boothbay Fund Management2 funds on PPLI.com | USD 845,000 | 0.0% |
| 22 | POINT72 Asset Management17 funds on PPLI.com | USD 410,000 | 0.0% |
| 23 | Brevan Howard Capital Management39 funds on PPLI.com | USD 372,000 | 0.0% |
| 24 | Engineers Gate Manager1 fund on PPLI.com | USD 329,000 | 0.0% |
| 25 | Scientech Research2 funds on PPLI.com | USD 229,000 | 0.2% |
| 26 | Freestone Grove Partners1 fund on PPLI.com | USD 25 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Fairmount Funds Management | USD 60m | 4.0% |
| 2 | ECOR1 Capital | USD 20m | 1.0% |
| 3 | Sio Capital Management | USD 5.3m | 0.9% |
| 4 | Exome Asset Management | USD 1.3m | 0.8% |
| 5 | Sphera Funds Management | USD 5.9m | 0.8% |
| 6 | Rock Springs Capital Management | USD 13m | 0.6% |
| 7 | Arrowmark Colorado Holdings | USD 15m | 0.6% |
| 8 | Scientech Research | USD 229,000 | 0.2% |
| 9 | Polar Capital LLP | USD 61m | 0.1% |
| 10 | Atom Investors | USD 943,000 | 0.1% |
Zenas BioPharma, Inc. trades under the symbol ZBIO on the Nasdaq. Its CUSIP, the code used on Form 13F, is 98937L105.
26 of the 720 hedge fund managers PPLI.com tracks reported Zenas BioPharma, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Polar Capital LLP (USD 61m), Fairmount Funds Management (USD 60m), Two Sigma Investments (USD 21m), ECOR1 Capital (USD 20m) and Millennium Management (USD 17m).
26 managers in our coverage reported it, and between them they run 346 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Fairmount Funds Management, where the position was 4.0% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Zenas BioPharma, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.